0001144204-17-005341.txt : 20170201 0001144204-17-005341.hdr.sgml : 20170201 20170201155126 ACCESSION NUMBER: 0001144204-17-005341 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170130 FILED AS OF DATE: 20170201 DATE AS OF CHANGE: 20170201 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Cytosorbents Corp CENTRAL INDEX KEY: 0001175151 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 980373793 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 7 DEER PARK DRIVE, SUITE K CITY: MONMOUTH JUNCTION STATE: NJ ZIP: 08852 BUSINESS PHONE: 973-329-8885 MAIL ADDRESS: STREET 1: 7 DEER PARK DRIVE, SUITE K CITY: MONMOUTH JUNCTION STATE: NJ ZIP: 08852 FORMER COMPANY: FORMER CONFORMED NAME: MedaSorb Technologies CORP DATE OF NAME CHANGE: 20060807 FORMER COMPANY: FORMER CONFORMED NAME: GILDER ENTERPRISES INC DATE OF NAME CHANGE: 20020611 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BLOCH KATHLEEN P. CENTRAL INDEX KEY: 0001409212 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36792 FILM NUMBER: 17564856 MAIL ADDRESS: STREET 1: 3 PERSHING COURT CITY: NORTH BRUNSWICK STATE: NJ ZIP: 08902 4 1 v458129_4.xml OWNERSHIP DOCUMENT X0306 4 2017-01-30 0 0001175151 Cytosorbents Corp CTSO 0001409212 BLOCH KATHLEEN P. C/O CYTOSORBENTS CORPORATION 7 DEER PARK DRIVE, SUITE K MONMOUTH JUNCTION NJ 08852 0 1 0 0 Chief Financial Officer Stock Option (right to buy) 4.69 2017-01-30 4 A 0 62000 0 A 2026-06-07 Common Stock 62000 62000 D On June 7, 2016, the reporting person was granted an option to purchase 77,500 shares of common stock pursuant to the CytoSorbents Corporation 2014 Long-Term Incentive Plan, which was to vest upon achievement of certain performance goals as determined in the discretion of the Board of Directors of CytoSorbents Corporation (the "Company"). This grant was reported on a Form 4 filed on June 9, 2016. On January 30, 2017, the Board of Directors of the Company determined that 80% of such performance criteria was achieved during 2016, resulting in the vesting of 62,000 shares underlying this option. /s/ Kathleen P. Bloch 2017-02-01